e-ISSN: Pending
WASTE Journal

Browse the failure-mode index

11,314 real negative results, null findings, and replication failures in Medicine · Negative / Null Result Report. Search the index →

WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record compiled from open scholarly databases; the abstract is shown in full only where the paper is openly licensed, otherwise a short excerpt under fair use. Classifications are automated and approximate.

Negative / Null Result ReportMedicine

Randomized Phase II Trial of Amrubicin Plus Irinotecan Versus Cisplatin Plus Irinotecan in Chemo-naïve Patients With Extensive-Disease Small-Cell Lung Cancer: Results of the Japan Multinational Trial Organization (JMTO) LC 08-01.

Yoshioka H, Ishida T, Atagi S et al. · 2025 · Clinical lung cancer

Background We conducted a randomize phase II study to evaluate the efficacy and safety of topoisomerase II inhibitor amrubicin plus topoisomerase I inhibitor irinotecan (AI) compared with cisplatin plus irinotecan (PI) as first-line…

View details →
Negative / Null Result ReportMedicine

Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer.

Pressiani T, Balsano R, Giordano L et al. · 2024 · European journal of cancer (Oxford, England : 1990)

Introduction The prognosis of patients with advanced biliary tract cancer (BTC) is still poor, and new strategies improving patients' outcome are needed. In our trial we investigated safety and activity of nab-paclitaxel in combination…

View details →
Negative / Null Result ReportMedicine

Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.

Gong J, Mita AC, Wei Z et al. · 2024 · JCO precision oncology

Purpose Despite fibroblast growth factor receptor ( FGFR ) inhibitors being approved in tumor types with select FGFR rearrangements or gene mutations, amplifications of FGFR represent the most common FGFR alteration across malignancies.…

View details →
Negative / Null Result ReportOpen accessMedicine

Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double-blind, placebo-controlled, Phase 2 study.

King B, Mesinkovska N, Senna M et al. · 2025 · Journal of the European Academy of Dermatology and Venereology : JEADV

Background Etrasimod, an oral, selective sphingosine 1-phosphate 1, 4 and 5 receptor modulator approved for the treatment of ulcerative colitis, has been studied in immune-mediated inflammatory diseases, including alopecia areata (AA).…

View details →
Negative / Null Result ReportOpen accessMedicine

Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis.

Hsu YC, Lin PT, Teng W et al. · 2024 · Cancers

Background The combination of anti-angiogenic therapy and immune checkpoint inhibitors has revolutionized the management of unresectable hepatocellular carcinoma (uHCC). While an early-phase study demonstrated promising outcomes for…

View details →
Negative / Null Result ReportMedicine

Multi-institutional feasibility study of intensity-modulated radiotherapy with chemotherapy for locally advanced non-small cell lung cancer.

Harada H, Omori S, Mori K et al. · 2022 · International journal of clinical oncology

Background This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC). Methods The major inclusion criteria were…

View details →
Negative / Null Result ReportMedicine

A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment.

Kerwin E, Dorinsky P, Patel M et al. · 2022 · The Journal of asthma : official journal of the Association for the Care of Asthma

Objective To evaluate the efficacy and safety of three doses of glycopyrrolate metered dose inhaler (GP MDI) in patients with uncontrolled asthma despite treatment with inhaled corticosteroid/long-acting β 2 -agonists (ICS/LABA) with or…

View details →
Negative / Null Result ReportOpen accessMedicine

Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis.

Kirschner P, Konen FF, Axhausen F et al. · 2026 · Therapeutic advances in neurological disorders

Background B-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS). Several case reports have raised concerns about new-onset or…

View details →
Negative / Null Result ReportOpen accessMedicine

Efficacy and Safety of the PD-1 Agonist JNJ-67484703 in Participants with Atopic Dermatitis: Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Results.

Cecchini M, Kwiek B, Liu-Walsh F et al. · 2026 · Dermatology and therapy

Introduction Atopic dermatitis (AD) is a chronic, inflammatory skin disease with a high burden and unmet needs. Herein, we have assessed the efficacy and safety of JNJ-67484703, a programmed cell death protein 1 (PD-1)-agonizing/depleting…

View details →
Negative / Null Result ReportOpen accessMedicine

Transanal versus robotic total mesorectal excision for mid- and low-rectal cancer: A single-center comparative cohort of 109 patients.

Lin CL, Chen MC, Lin CY et al. · 2026 · Journal of robotic surgery

Minimally invasive total mesorectal excision (TME) for rectal cancer can be performed via transanal TME (TaTME) or robotic TME (R-TME), yet comparative evidence in predominantly non-obese Asian cohorts remains limited. We evaluated a…

View details →
Negative / Null Result ReportOpen accessMedicine

A Single-Arm Phase 2 Trial of Doxorubicin Plus Zalifrelimab (Anti-CTLA-4 Antibody) and Balstilimab (Anti-PD-1 Antibody) in Advanced/Metastatic Soft Tissue Sarcomas.

Wilky BA, Julian KA, Maleddu A et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research

Purpose Doxorubicin is standard chemotherapy for metastatic soft tissue sarcomas (STS) but also enhances innate/adaptive immune responses by inducing immunogenic cell death. Most STS are immune "cold" tumors that do not respond to immune…

View details →
Negative / Null Result ReportOpen accessMedicine

Lurbinectedin in small cell lung cancer.

Manzo A, Sforza V, Carillio G et al. · 2022 · Frontiers in oncology

Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works…

View details →
Negative / Null Result ReportOpen accessMedicine

Does the Benefit of Thrombectomy in Large Strokes Depend on Perfusion-Diffusion Mismatch? A Large Stroke Therapy Evaluation Trial Post Hoc Analysis.

Schiphorst AT, Arquizan C, Turc G et al. · 2026 · Journal of stroke

Background and purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large…

View details →
Negative / Null Result ReportOpen accessMedicine

Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial results.

Levy A, Morel D, Texier M et al. · 2025 · Signal transduction and targeted therapy

Immunoradiotherapy holds promise for improving outcomes in patients with advanced solid tumors, including in soft-tissue sarcoma (STS). However, the ideal combination of treatment modalities remains to be determined, and reliable…

View details →
Negative / Null Result ReportOpen accessMedicine

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.

Lenz HJ, Parikh A, Spigel DR et al. · 2024 · Journal for immunotherapy of cancer

Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in…

View details →
Negative / Null Result ReportOpen accessMedicine

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

Geurts VCM, Voorwerk L, Balduzzi S et al. · 2023 · Breast (Edinburgh, Scotland)

The large majority of patients with HER2-positive metastatic breast cancer (MBC) will eventually develop resistance to anti-HER2 therapy and die of this disease. Despite, relatively high levels of stromal tumor infiltrating lymphocytes…

View details →
Negative / Null Result ReportMedicine

NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.

Rimel BJ, Enserro D, Bender DP et al. · 2024 · Cancer

Purpose This paper reports the efficacy of the poly (ADP-ribose) polymerase inhibitor olaparib alone and in combination with the antiangiogenesis agent cediranib compared with cediranib alone in patients with advanced endometrial cancer.…

View details →
Negative / Null Result ReportMedicine

Belimumab treatment of adult idiopathic inflammatory myopathy.

Marder G, Quach T, Chadha P et al. · 2024 · Rheumatology (Oxford, England)

Objective To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). Methods We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV…

View details →
Negative / Null Result ReportOpen accessMedicine

A phase 0, window of opportunity study of parasympathetic stimulation with bethanechol in localized pancreatic adenocarcinoma prior to surgery.

White RA, Mezzano-Robinson V, Shi Q et al. · 2025 · The oncologist

Background The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine…

View details →